HEPARIN, LOW MOLECULAR WEIGHT
- HEPARIN, LOW MOLECULAR WEIGHT
- Start Date
- Expiration Date
- CPT Codes
- Reference Test
Platelet-poor plasma (PPP) samples obtained by double centrifugation are critical for accurate coagulation studies as platelet contamination may cause spurious results
2.0 mL (Two aliquots, 1.0 mL each)
- Transport Info
Separate plasma from cells immediately
• Promptly centrifuge 15 minutes
• Carefully transfer plasma portion of sample to separate plastic tube using plastic pipette
• Centrifuge transferred plasma sample again to produce platelet-poor plasma (PPP)
• Use second plastic pipette to carefully transfer PPP sample into 2 plastic aliquot tubes
- Fasting Required?
- Patient Instructions
Separate plasma from cells immediately - Promptly, centrifuge 15 minutes - Immediately carefully transfer plasma portion of sample to separate plastic tube using plastic pipette Note: Buffy coat layer of sample must be avoided - Centrifuge transferred plasma sample again to produce platelet-poor plasma (PPP) - Use second plastic pipette to carefully transfer at least 0.5 mL PPP into each of 2 plastic aliquot tubes (total sample volume: at least 1.0 mL) - Within 4 hours of collection, freeze both PPP samples.
- Reference Range
Therapeutic range varies with the type and manufacturer.
0.5-1.1 U/mL based on Lovenox (enoxaparin sodium).
Heparin by itself exhibits little anticoagulant activity. It requires a plasma cofactor, Antithrombin III, for its anticoagulant activity. Specifically, heparin is a catalyst that accelerates the neutralization of activated clotting factors such as Factor Xa and thrombin.The inhibition of Factor Xa by Antithrombin III is accelerated by heparin. Under optimum conditions the amount of Factor Xa activity neutralized during a predetermined time period is directly proportional to the concentration of heparin in the reaction mixture.